Materialise NV【MTLS】株式ニュース

Materialise Reports First Quarter 2026 ResultsMay 7, 2026 1:00 AM
Business Wire Materialise transfers eyewear business to its management team Regulated information1 Materialise NV (Euronext & NASDAQ:MTLS), a global leader in 3D-printed medical devices and software, and a pioneer in additive manufacturing software and services, today announced its financial results for the first quarter ended March 31, 2026. Additionally, Materialise announced the transfer of its eyewear business to the eyewear management team. Highlights – First Quarter 2026 Total revenue was stable at 66,276 kEUR for the first quarter of 2026 compared to 66,379 kEUR for the corresponding 2025 period. Gross profit as a percentage of revenue for the first quarter of 2026 increased to 57.2%, compared to 55.3% for the corresponding 2025 period. Adjusted EBIT increased to 2,470 kEUR for the first quarter of 2026 from 646 kEUR for the first quarter of 2025. Net result for the first quarter of 2026 was 1,820 kEUR, or 0.03 EUR per diluted share, compared to a net loss of (535) kEUR, or (0.01) EUR per diluted share, for the corresponding 2025 period. Driven by recurring positive free cash flow, our net cash position increased by 2,021 kEUR over the quarter to 72,826 kEUR, while 2,308 kEUR was invested in share buybacks, underscoring strong cash generation. CEO Brigitte de Vet-Veithen commented, “In a quarter where elevated geopolitical uncertainty and unfavorable foreign currency exchange movements weighed on our revenue growth, we improved operational profitability across all business segments through operational focus and continued cost control. We closed the quarter with positive operating and free cash flow and a further improved net cash position, reinforcing the strength of our balance sheet and providing us with the flexibility to continue investing in innovation and growth. Following the sale of our Rapidfit business at the end of March of this year, we have now also reached an agreement to transfer our eyewear activities to the business’s management team. We believe these decisive portfolio actions will allow Materialise to further concentrate capital and resources on its core focus areas, while enabling both Rapidfit and Eyewear to operate in a setup that will best support their next phase of growth.” _________________ 1 The enclosed information constitutes regulated information as defined in the Belgian Royal Decree of 14 November 2007 regarding the duties of issuers of financial instruments which have been admitted for trading on a regulated market. First Quarter 2026 Results Total revenue for the first quarter of 2026 was stable at 66,276 kEUR from 66,379 kEUR for the first quarter of 2025. Adjusted EBIT for the first quarter of 2026 increased to 2,470 kEUR compared to 646 kEUR for the 2025 period. The Adjusted EBIT margin (Adjusted EBIT divided by total revenue) for the first quarter of 2026 was 3.7%, compared to 1.0% for the first quarter of 2025. Adjusted EBITDA for the first quarter of 2026 increased to 8,049 kEUR compared to 6,147 kEUR for the 2025 period. Revenue from our Materialise Medical segment increased 6.7% to 33,165 kEUR for the first quarter of 2026 compared to 31,078 kEUR for the same period in 2025. Segment Adjusted EBITDA increased 2.1% to 9,235 kEUR for the first quarter of 2026 compared to 9,047 kEUR, while the segment Adjusted EBITDA margin was 27.8% compared to 29.1% for the first quarter of 2025. Revenue from our Materialise Software segment decreased 1.4% to 9,641 kEUR for the first quarter of 2026 from 9,775 kEUR for the same quarter last year. Segment Adjusted EBITDA increased 87.4% to 1,123 kEUR from 599 kEUR, while the segment Adjusted EBITDA margin increased to 11.6%, compared to 6.1% for the prior-year period. Revenue from our Materialise Manufacturing segment decreased 8.1% to 23,470 kEUR for the first quarter of 2026 from 25,526 kEUR for the first quarter of 2025. Segment Adjusted EBITDA increased to 281 kEUR compared to (377) kEUR, while the segment Adjusted EBITDA margin increased to 1.2% compared to (1.5)% for the first quarter of 2025. Gross profit increased 3.2% to 37,894 kEUR compared to 36,724 kEUR for the same period last year, while gross profit as a percentage of revenue increased to 57.2% compared to 55.3% for the first quarter of 2025. Research and development (“R&D”), sales and marketing (“S&M”), and general and administrative (“G&A”) expenses remained stable, in the aggregate, at 36,713 kEUR for the first quarter of 2026 from 36,510 kEUR for the first quarter of 2025. Net other operating income was 909 kEUR compared to 360 kEUR for the first quarter of 2025. Operating result increased to 2,090 kEUR compared to 574 kEUR for the first quarter of 2025, while net financial result was 392 kEUR, compared to (875) kEUR for the first quarter of 2025. The first quarter of 2026 contained net tax expenses of (662) kEUR, compared to net tax expenses of (234) kEUR in the first quarter of 2025. As a result of the above, net profit for the first quarter of 2026 increased to 1,820 kEUR, compared to a net loss of (535) kEUR for the same period in 2025. Total comprehensive income for the first quarter of 2026, which includes exchange differences on translation of foreign operations, was 2,374 kEUR compared to (30) kEUR for the 2025 period. At March 31, 2026, we had cash and cash equivalents of 132,952 kEUR compared to 133,918 kEUR at December 31, 2025. Gross debt amounted to 60,126 kEUR, compared to 63,113 kEUR at December 31, 2025. As a result, our net cash position increased by 2,021 kEUR to 72,826 kEUR. At the end of the first quarter of 2026 Materialise had bought back 511,513 own shares for a total amount (excluding transaction cost) of 2,308 kEUR (2,722 kUSD) under the previously announced share buy-back program. Cash flow from operating activities for the first quarter of 2026 was 6,914 kEUR. Total cash out from capital expenditures for the first quarter of 2026 amounted to 1,470 kEUR resulting in a positive free cash flow. Net shareholders’ equity at March 31, 2026 was 255,595 kEUR compared to 255,482 kEUR at December 31, 2025. On April 23, 2026, Materialise released its 2025 Annual Report, including its CSRD report, outlining the integration of sustainability into its corporate strategy. With this integrated report we aim at providing transparency on our corporate matters, our financial performance in 2025 and on the initiatives we are taking to make a sustainable difference with additive manufacturing for a better and healthier world. The report is available on our corporate website or can be accessed directly through https://investors.materialise.com/financials/reports. Materialise to transfer eyewear business to its management team Today, Materialise announces it has reached an agreement to transfer its eyewear business to the business’s management team. We believe the transaction aligns with Materialise’s strategy to sharpen its portfolio and to further concentrate capital and resources on its core focus areas, while enabling both Rapidfit and Eyewear to operate in a setup that will best support their next phase of growth. Materialise will retain a minority stake in the newly formed eyewear company, reflecting its continued confidence in the business. All employees currently supporting the eyewear business will transition to the new company formed in connection with the transfer. The financial terms of the transaction were not publicly disclosed, and we expect to recognize impairment charges in the second quarter of 2026 related to the transaction. 2026 Guidance Mrs. de Vet-Veithen concluded, “As previously communicated in our guidance issued in February, we expect macro-economic and geopolitical uncertainty to persist throughout fiscal year 2026. Nevertheless, we continue to have confidence in the strength and resilience of our underlying business fundamentals. The strategic repositioning initiatives and targeted investments across our three business segments are expected to progressively support operational performance and profitable growth. Notwithstanding the anticipated impact of the divestments of Rapidfit and Eyewear, we reaffirm our full-year revenue guidance for fiscal year 2026 in the range of 273,000 to 283,000 kEUR. In addition, we are maintaining our Adjusted EBIT guidance for fiscal year 2026 of 10,000 to 12,000 kEUR, reflecting our continued focus on execution discipline, cost management, and capital allocation.” Non-IFRS Measures Materialise uses EBIT, EBITDA, Adjusted EBIT and Adjusted EBITDA as supplemental financial measures of its financial performance, including for purposes of monitoring compliance with financial covenants, supporting discussions with financing institutions, and meeting reporting requirements to our banks. EBIT is calculated as net profit plus income taxes, financial expenses (less financial income) and shares of profit or loss in a joint venture. EBITDA is calculated as net profit plus income taxes, financial expenses (less financial income), shares of profit or loss in a joint venture and depreciation and amortization. Adjusted EBIT and Adjusted EBITDA are determined by adding to EBIT and EBITDA, respectively (i) share-based compensation expenses, (ii) acquisition expenses related to business combinations or divestiture-related expenses, (iii) impairments and revaluation of fair value due to business combinations and (iv) costs incurred in relation to corporate initiatives, restructurings or reorganizations that are of a non-recurring nature. Management believes these non-IFRS measures to be important measures as they exclude the effects of items which primarily reflect the impact of financing decisions and, in the case of EBITDA and Adjusted EBITDA, long term investment, rather than the performance of the company’s day-to-day operations. The company also uses segment Adjusted EBITDA and segment Adjusted EBITDA margin to evaluate the performance of its three business segments. As compared to net profit, these measures are limited in that they do not reflect the cash requirements necessary to service interest or principal payments on the company’s indebtedness and, in the case of EBITDA and Adjusted EBITDA, these measures are further limited in that they do not reflect the periodic costs of certain capitalized tangible and intangible assets used in generating revenues in the company’s business, or the changes associated with impairments. Management evaluates such items through other financial measures such as financial expenses, capital expenditures and cash flow provided by operating activities. The company believes that these measurements are useful to measure a company’s ability to grow or as a valuation measurement. The company’s calculation of EBIT, EBITDA, Adjusted EBIT and Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. EBIT, EBITDA, Adjusted EBIT and Adjusted EBITDA should not be considered as alternatives to net profit or any other performance measure derived in accordance with IFRS. The company’s presentation of EBIT, EBITDA, Adjusted EBIT and Adjusted EBITDA should not be construed to imply that its future results will be unaffected by unusual or non-recurring items. Exchange Rate This document contains translations of certain euro amounts into U.S. dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from euros to U.S. dollars in this document were made at a rate of EUR 1.00 to USD 1.1498, the reference rate of the European Central Bank on March 31, 2026. Conference Call and Webcast Materialise will hold a conference call and simultaneous webcast to discuss its financial results for the first quarter of 2026 on Thursday, May 7, 2026, at 8:30 a.m. ET/2:30 p.m. CET. Company participants on the call will include Brigitte de Vet-Veithen, Chief Executive Officer and Koen Berges, Chief Financial Officer. A question-and-answer session will follow management’s remarks. To access the call by phone, please click the link below at least 15 minutes prior to the scheduled start time and you will be provided with dial-in details. Participants can choose to dial in or receive a call to connect to Materialise’s conference call. https://register-conf.media-server.com/register/BI7e584baacee14013bd0ffd0406fb9ccd The conference call will also be broadcast live over the Internet with an accompanying slide presentation, which can be accessed on the company’s website at http://investors.materialise.com. The webcast of the conference call will be archived on the company's website for one year. About Materialise Materialise NV incorporates more than three decades of 3D printing experience into a range of software solutions and 3D printing services that empower sustainable 3D printing applications. Our open, secure, and innovative end-to-end solutions enable flexible industrial manufacturing and mass personalization in various industries — including healthcare, automotive, aerospace, eyewear, art and design, wearables, and consumer goods. Headquartered in Belgium and with branches worldwide, Materialise NV combines the largest group of software developers in the industry with one of the world's largest and most complete 3D printing facilities. For additional information, please visit: www.materialise.com. Cautionary Statement on Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, our intentions, beliefs, assumptions, projections, outlook, analyses or current expectations, plans, objectives, strategies and prospects, both financial and business, including statements concerning, among other things, our estimates for the current fiscal year’s revenue and Adjusted EBIT, our results of operations, cash needs, capital expenditures, expenses, financial condition, liquidity, prospects, divestitures, growth and strategies (including how our business, results of operations and financial condition could be impacted by the current armed geopolitical conflicts around the world and governmental responses thereto, inflation, increased labor, energy and materials costs), policy changes resulting from the U.S. presidential administration, changes in tariffs and trade restrictions, and the trends and competition that may affect the markets, industry or us. Such statements are subject to known and unknown uncertainties and risks. When used in this press release, the words “estimate,” “expect,” “anticipate,” “project,” “plan,” “intend,” “believe,” “forecast,” “will,” “may,” “could,” “might,” “aim,” “should,” and variations of such words or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the expectations of management under current assumptions at the time of this press release. These expectations, beliefs and projections are expressed in good faith and the company believes there is a reasonable basis for them. However, the company cannot offer any assurance that our expectations, beliefs and projections will actually be achieved. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and industry change, and depend on economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. We caution you that forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. All of the forward-looking statements are subject to risks and uncertainties that may cause the company's actual results to differ materially from our expectations, including risk factors described in the company's most recent annual report on Form 20-F filed with the U.S. Securities and Exchange Commission. There are a number of risks and uncertainties that could cause the company's actual results to differ materially from the forward-looking statements contained in this press release. The company is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise, unless it has obligations under the federal securities laws to update and disclose material developments related to previously disclosed information. Consolidated income statements (Unaudited) for the three months ended
March 31, In '000 2026 2026 2025 U.S.$ € € Revenue 76,204 66,276 66,379 Cost of Sales (32,634) (28,383) (29,654) Gross Profit 43,570 37,894 36,724 Gross profit as % of revenue 57.2% 57.2% 55.3% Research and development expenses (13,671) (11,890) (11,414) Sales and marketing expenses (17,748) (15,435) (15,071) General and administrative expenses (10,793) (9,387) (10,025) Net other operating income (expenses) 1,045 909 360 Operating (loss) profit 2,403 2,090 574 Financial expenses (804) (700) (2,772) Financial income 1,256 1,092 1,897 (Loss) profit before taxes 2,855 2,483 (301) Income Taxes (762) (662) (234) Net (loss) profit for the period 2,093 1,820 (535) Net (loss) profit attributable to: The owners of the parent 2,093 1,820 (533) Non-controlling interest - - (2) Earning per share attributable to owners of the parent Basic 0.04 0.03 (0.01) Diluted 0.04 0.03 (0.01) Weighted average basic shares outstanding 58,865 58,865 59,067 Weighted average diluted shares outstanding 58,865 58,865 59,067 Consolidated statements of comprehensive income (Unaudited) for the three months ended
March 31, In 000€ 2026 2026 2025 U.S.$ € € Net profit (loss) for the period 2,093 1,820 (535) Other comprehensive income Recycling Exchange difference on translation of foreign operations 637 554 505 Non-recycling Fair value adjustments through OCI - - - Other comprehensive income (loss), net of taxes 637 554 505 Total comprehensive income (loss) for the year, net of taxes 2,730 2,374 (30) Total comprehensive income (loss) attributable to: The owners of the parent 2,733 2,377 (32) Non-controlling interests (3) (3) 1 Consolidated statement of financial position (Unaudited) As of
March 31, As of
December 31, In 000€ 2026 2025 Assets Non-current assets Goodwill 43,171 43,161 Intangible assets 24,589 25,639 Property, plant & equipment 111,635 112,854 Right-of-Use assets 5,774 5,429 Deferred tax assets 3,834 3,971 Other non-current assets 5,249 5,983 Total non-current assets 194,253 197,038 Current assets Inventories 16,753 14,904 Trade receivables 55,462 54,938 Other current assets 14,924 15,533 Cash and cash equivalents 132,952 133,918 Assets held for sale 4,183 4,314 Total current assets 224,274 223,607 Total assets 418,527 420,646 As of
March 31, As of
December 31, In 000€ 2026 2025 Equity and liabilities Equity Share capital 4,487 4,487 Share premium 203,895 203,895 Treasury Shares (2,308) - Retained earnings and other reserves 49,604 47,180 Equity attributable to the owners of the parent 255,678 255,562 Non-controlling interest (83) (80) Total equity 255,595 255,482 Non-current liabilities Loans & borrowings 47,190 49,726 Lease liabilities 3,299 3,063 Deferred tax liabilities 2,566 2,660 Deferred income 16,845 17,344 Other non-current liabilities 321 486 Total non-current liabilities 70,221 73,280 Current liabilities Loans & borrowings 6,824 7,759 Lease liabilities 2,813 2,565 Trade payables 19,783 20,125 Tax payables 869 748 Deferred income 44,165 43,523 Other current liabilities 18,088 16,362 Liabilities held for sale 168 802 Total current liabilities 92,711 91,884 Total equity and liabilities 418,527 420,646 Consolidated statement of cash flows (Unaudited) for the three months
ended March 31, In 000€ 2026 2025 Operating activities Net (loss) profit for the period 1,820 (535) Non-cash and operational adjustments 5,820 6,994 Depreciation of property plant & equipment 3,999 3,854 Amortization of intangible assets 1,651 1,631 Share-based payment expense 56 72 Loss (gain) on disposal of intangible assets and property, plant & equipment (54) 21 Government grants (112) - Movement in provisions (156) 18 Movement reserve for bad debt and slow moving inventory 196 243 Financial income (1,111) (1,834) Financial expense 722 2,763 Impact of foreign currencies (34) (2) (Deferred) income taxes 663 228 Working capital adjustments (1,693) 3,763 Decrease (increase) in trade receivables and other receivables 50 4,487 Decrease (increase) in inventories and contracts in progress (1,933) 948 Increase (decrease) in deferred revenue 71 1,868 Increase (decrease) in trade payables and other payables 119 (3,539) Income tax paid 326 (1,140) Interest received 640 631 Net cash flow from operating activities 6,914 9,713 for the three months ended
March 31, In 000€ 2026 2025 Investing activities Purchase of property, plant & equipment (969) (1,400) Purchase of intangible assets (501) (432) Proceeds from the sale of property, plant & equipment & intangible assets (net) 70 75 Capital government grants received 229 - Net cash flow used in investing activities (1,171) (1,757) Financing activities Repayment of loans & borrowings (3,459) (4,472) Repayment of leases (751) (815) Interest paid (473) (235) Other financial income (expense) 19 (310) Repurchase of treasury shares (2,317) - Net cash flow from (used in) financing activities (6,982) (5,832) Net increase/(decrease) of cash & cash equivalents (1,238) 2,123 Cash & Cash equivalents at the beginning of the year 133,918 102,304 Exchange rate differences on cash & cash equivalents 329 (247) Cash & cash equivalents at end of the period 133,009 104,180 Reconciliation of Net Profit (Loss) to EBITDA and Adjusted EBITDA (Unaudited) for the three months ended
March 31, In 000€ 2026 2025 Net profit (loss) for the period 1,820 (535) Income taxes 662 234 Financial expenses 700 2,772 Financial income (1,092) (1,897) Depreciation and amortization 5,578 5,501 EBITDA 7,669 6,075 Share-based compensation expense (1) 56 72 Restructuring and corporate initiatives (2) 257 - Impairments (3) 67 - Adjusted EBITDA 8,049 6,147 (1) Share-based compensation expense represents the cost of equity-settled and share-based payments to employees. (2) Non-recurring costs related to corporate initiatives, restructurings or reorganizations (3) Impairments represent the impairment of tangible and intangible assets of RapidFit NV resulting from the asset transfer to its management. Reconciliation of Net Profit (Loss) to EBIT and Adjusted EBIT (Unaudited) for the three months ended
March 31, In 000€ 2026 2025 Net profit (loss) for the period 1,820 (535) Income taxes 662 234 Financial expenses 700 2,772 Financial income (1,092) (1,897) EBIT 2,090 574 Share-based compensation expense (1) 56 72 Restructuring and corporate initiatives (2) 257 - Impairments (3) 67 - Adjusted EBIT 2,470 646 (1) Share-based compensation expense represents the cost of equity-settled and share-based payments to employees. (2) Non-recurring costs related to corporate initiatives, restructurings or reorganizations (3) Impairments represent the impairment of tangible and intangible assets of RapidFit NV resulting from the asset transfer to its management. Segment P&L (Unaudited) In 000€ Materialise
Medical Materialise
Software Materialise
Manufacturing Total
segments Unallocated (1) Consolidated For the three months ended March 31, 2026 Revenues 33,165 9,641 23,470 66,276 0 66,276 Segment (adj) EBITDA 9,235 1,123 281 10,638 (2,589) 8,049 Segment (adj) EBITDA % 27.8% 11.6% 1.2% 16.1% 12.1% For the three months ended March 31, 2025 Revenues 31,078 9,775 25,526 66,379 0 66,379 Segment (adj) EBITDA 9,047 599 (377) 9,269 (3,122) 6,147 Segment (adj) EBITDA % 29.1% 6.1% -1.5% 14.0% 9.3% (1) Unallocated segment adjusted EBITDA consists of corporate research and development and corporate other operating income (expense), and the added share-based compensation expenses, acquisition expenses related to business combinations or divestiture-related expenses, impairments and revaluation of fair value of business combinations and non-recurring costs related to corporate initiatives, restructurings and reorganizations that are included in Adjusted EBITDA and that are not allocated to the reporting segments . Reconciliation of Net Profit (Loss) to Segment adjusted EBITDA (Unaudited) for the three months ended
March 31, In 000€ 2026 2025 Net profit (loss) for the period 1,820 (535) Income taxes 662 234 Financial expenses 700 2,772 Financial income (1,092) (1,897) Operating (loss) profit 2,090 574 Depreciation and amortization 5,578 5,501 Corporate research and development 878 1,030 Corporate headquarter costs 2,998 2,852 Other operating income (expense) (974) (688) Impairments (1) 67 - Segment adjusted EBITDA 10,638 9,269 (1) Impairments represent the impairment of tangible and intangible assets of RapidFit NV resulting from the asset transfer to its management. View source version on businesswire.com: https://www.businesswire.com/news/home/20260506559136/en/ Investor Relations Contact Harriet Fried
Alliance Advisors Investor Relations
212.838.3777
hfried@allianceadvisors.com Original: Materialise Reports First Quarter 2026 Results

Materialise Reports Fourth Quarter and Full Year 2025 ResultsFebruary 19, 2026 1:00 AM
Business Wire
Regulated information1

Materialise NV (Euronext & NASDAQ:MTLS), a global leader in 3D-printed medical devices and software, and a pioneer in additive manufacturing software and services, today announced its financial results for the fourth quarter and full year ended December 31, 2025.

Highlights – Fourth Quarter 2025

Total revenue increased by 6.8% to 70,164 kEUR for the fourth quarter of 2025 from 65,680 kEUR for the corresponding 2024 period, boosted by 16.3% growth in our Materialise Medical segment.

Gross profit as a percentage of revenue for the fourth quarter of 2025 increased to 58.1%, compared to 55.4% for the corresponding 2024 period.

Adjusted EBIT amounted to 3,980 kEUR for the fourth quarter of 2025, representing 5.7% of consolidated revenue, compared to (1,195) kEUR for the corresponding period.

Net result for the fourth quarter of 2025 was 6,206 kEUR, or 0.11 EUR per diluted share, compared to a net result of 2,907 kEUR, or 0.05 EUR per diluted share, for the corresponding 2024 period.

Highlights – Full Year 2025

Total revenue remained stable at 267,633 kEUR for 2025 compared to 266,765 kEUR for 2024, fueled by strong 15.4% growth in our Materialise Medical segment which was offset by lower revenues in our Materialise Manufacturing segment and unfavourable foreign exchange effects.

Gross profit as a percentage of revenue for 2025 increased to 57.1%, compared to 56.5% for 2024.

Adjusted EBITDA increased to 32,386 kEUR for 2025 compared to 31,484 kEUR for 2024. Adjusted EBIT increased to 10,601 kEUR for 2025 from 9,741 kEUR for 2024.

Net profit for 2025 was 7,716 kEUR, or 0.13 EUR per diluted share, compared to a net profit of 13,406 kEUR, or 0.23 EUR per diluted share, for 2024.

Total cash reserves amounted to 133,918 kEUR at the end of 2025.

CEO Brigitte de Vet-Veithen commented, “In the final quarter of 2025, we reached a major milestone with our successful Euronext listing and the announcement of a strategic share buyback program. These steps clearly demonstrate our commitment to delivering long-term shareholder value. We achieved nearly 7% revenue growth and delivered a substantial improvement in operational profitability compared to the fourth quarter of 2024. Our Materialise Medical segment continues to lead the way, achieving another quarterly revenue record and sustaining its double-digit growth path. Our Materialise Software segment maintained steady upward momentum, continuing to build on successive quarterly revenue increases throughout 2025. While our Materialise Manufacturing segment continued to be impacted by soft prototyping demand, its strategic transition towards series manufacturing led to key commercial wins in targeted aerospace and defense markets that we expect will contribute to our results in coming periods. Throughout the last quarter of 2025 we further executed focused cost control measures without compromising R&D investments. With 134 million EUR of cash and cash equivalents on our balance sheet, an improved net cash position and consistently positive operating cash flow, we believe we are financially strong and well-positioned to further drive innovation and capture emerging market opportunities.”

_________________

1 The enclosed information constitutes regulated information as defined in the Belgian Royal Decree of 14 November 2007 regarding the duties of issuers of financial instruments which have been admitted for trading on a regulated market.

Fourth Quarter 2025 Results

Total revenue for the fourth quarter of 2025 increased 6.8% to 70,164 kEUR from 65,680 kEUR for the fourth quarter of 2024. Adjusted EBITDA increased to 9,524 kEUR for the fourth quarter of 2025 from 4,306 kEUR for the 2024 period. Adjusted EBIT amounted to 3,980 kEUR, compared to (1,195) kEUR for the same period in 2024.

Revenue from our Materialise Medical segment increased 16.3% to 37,016 kEUR for the fourth quarter of 2025, compared to 31,837 kEUR for the same period in 2024. Adjusted EBITDA for the segment was 13,024 kEUR compared to 9,547 kEUR, while the Adjusted EBITDA margin for the segment was 35.2%, compared to 30.0% for the prior-year period.

Revenue from our Materialise Software segment decreased 1.3% to 10,974 kEUR from 11,124 kEUR for the same quarter last year. Adjusted EBITDA for the segment amounted to 1,701 kEUR compared to 1,123 kEUR, while the Adjusted EBITDA margin for the segment was 15.5%, compared to 10.1% for the prior-year period.

Revenue from our Materialise Manufacturing segment decreased 2.4% to 22,174 kEUR from 22,719 kEUR for the fourth quarter of 2024. Adjusted EBITDA for the segment increased to (2,199) kEUR compared to (2,989) kEUR, while the Adjusted EBITDA margin for the segment was (9.9)% compared to (13.2)% for the prior-year period.

Consolidated gross profit increased 12.2% to 40,791 kEUR for the fourth quarter of 2025 from 36,365 kEUR for the same period last year. Gross profit as a percentage of revenue improved to 58.1%, compared to 55.4%.

Research and development (“R&D”), sales and marketing (“S&M”), and general and administrative (“G&A”) expenses remained in aggregate stable at 38,938 kEUR for the fourth quarter of 2025 compared to 38,990 kEUR for the prior year period, while the fourth quarter of 2025 included non-recurring costs related to the Euronext listing of 750 kEUR.

Net other operating income decreased to 1,258 kEUR compared to 1,357 kEUR for the fourth quarter of 2024.

The operating result was 3,111 kEUR, compared to (1,268) kEUR for the fourth quarter of 2024.

Net financial result for the fourth quarter of 2025 was 2,400 kEUR, compared to 3,301 kEUR for the corresponding period of 2024.

The fourth quarter of 2025 contained net tax income of 695 kEUR, compared to 874 kEUR for the fourth quarter of 2024.

As a result of the above, net profit for the fourth quarter of 2025 was 6,206 kEUR, compared to 2,907 kEUR for the same period in 2024.

At December 31, 2025, we reported 133,918 kEUR cash and cash equivalents on our balance sheet compared to 102,304 kEUR at December 31, 2024. Gross debt amounted to 63,113 kEUR compared to 41,284 kEUR at December 31, 2024. As a result, our net cash position (cash and cash equivalents less gross debt) was 70,805 kEUR, an increase of 9,785 KEUR compared to December 31, 2024.

Cash flow from operating activities for the fourth quarter of the year 2025 was 5,274 kEUR, compared to 6,218 kEUR for the same period in 2024. Total capital expenditures for the fourth quarter of the year 2025 amounted to 4,411 kEUR. The generated free cash flow over the fourth quarter of 2025 amounted to 4,511 kEUR.

Net shareholders’ equity at December 31, 2025 was 255,482 kEUR compared to 248,492 kEUR at December 31, 2024, representing an increase of 2.8%.

Full Year 2025 Results

Total revenues for the year ended December 31, 2025 remained stable at 267,633 kEUR compared to 266,765 kEUR for the year ended December 31, 2024. Adjusted EBITDA for 2025 improved to 32,386 kEUR compared to 31,484 kEUR for 2024. The Adjusted EBITDA margin improved to 12.1% in 2025, compared to 11.8% in 2024. Adjusted EBIT for 2025 increased to 10,601 kEUR compared to 9,741 kEUR for 2024. The Adjusted EBIT margin for 2025 increased to 4.0%, compared to 3.7% for 2024.

Revenues from our Materialise Medical segment grew by 15.4% for the year ended December 31, 2025 to 134,239 kEUR from 116,358 kEUR for the year ended December 31, 2024. The segment’s Adjusted EBITDA increased to 42,983 kEUR from 35,562 kEUR. The segment’s Adjusted EBITDA margin improved to 32.0% in 2025, compared to 30.6% in 2024.

Revenues from our Materialise Software segment decreased 6.8% to 40,907 kEUR for the year ended December 31, 2025 compared to 43,899 kEUR for the year ended December 31, 2024. The segment’s Adjusted EBITDA decreased to 5,469 kEUR from 5,562 kEUR in 2024. The segment’s Adjusted EBITDA margin improved to 13.4% in 2025, compared to 12.7% in 2024.

Revenues from our Materialise Manufacturing segment decreased 13.2% to 92,486 kEUR for the year ended December 31, 2025 from 106,508 kEUR for the year ended December 31, 2024. The segment’s Adjusted EBITDA amounted to (4,236) kEUR compared to 1,660 kEUR. The segment’s Adjusted EBITDA margin was (4.6)% in 2025, compared to 1.6% in 2024.

Consolidated gross profit increased 1.4% to 152,949 kEUR from 150,826 kEUR last year. Gross profit as a percentage of revenue increased to 57.1%, compared to 56.5% in 2024.

Research and development (“R&D”) expenses increased by 3.8% to 46,089 kEUR mainly reflecting higher investments in our Materialise Medical segment. Other operational expenses, including sales and marketing (“S&M”) and general and administrative (“G&A”) expenses, increased in aggregate over the full year 2025 by only 0.5% compared to 2024 to 101,714 kEUR.

Net other operating income was 3,789 kEUR compared to 4,223 kEUR for 2024.

Operating result amounted to 8,936 kEUR for the year ended December 31, 2025 compared to 9,432 kEUR in the prior year.

Net financial result amounted to (1,648) kEUR, compared to net financial result of 4,707 kEUR for the year ended December 31, 2024 reflecting the significantly higher impact of unfavorable exchange rate fluctuations in 2025.

Income taxes amounted to 429 kEUR compared to (733) kEUR for the year ended December 31, 2024.

As a result, net profit was 7,716 kEUR for 2025 compared to a net profit of 13,406 kEUR in 2024.

Cash flow from operating activities for the year ended December 31, 2025 was 25,319 kEUR compared to 31,456 kEUR for the year ended December 31, 2024. Total capital expenditures for the year ended December 31, 2025 amounted to 16,261 kEUR. The generated free cash flow over 2025 amounted to 15,615 kEUR.

2026 Guidance

Mrs. de Vet-Veithen concluded, “Also for fiscal year 2026, we expect our three reporting segments to evolve at a different pace. We anticipate continued strong revenue growth from our Materialise Medical segment. Our Materialise Software segment will complete the transition towards a cloud-based subscription business model, and will continue its investments in a broader AM software ecosystem covering end-to-end workflows. Our Materialise Manufacturing segment will intensify its ongoing shift towards series manufacturing and dedicated focus sectors, but we expect macroeconomic headwinds in the industrial market segments to persist throughout 2026.

On a consolidated level, we therefore expect our full year revenues for 2026 to grow to a range of 273,000 to 283,000 kEUR. We will continue investing in our Materialise Medical and Software segments while maintaining disciplined cost control and optimization, in particular in our Materialise Manufacturing segment and in our overhead. As a result, we expect our Adjusted EBIT to reach 10,000 to 12,000 kEUR for fiscal year 2026.”

Non-IFRS Measures

Materialise uses EBIT, EBITDA, Adjusted EBIT and Adjusted EBITDA as supplemental financial measures of its financial performance. EBIT is calculated as net profit plus income taxes, financial expenses (less financial income) and shares of profit or loss in a joint venture. EBITDA is calculated as net profit plus income taxes, financial expenses (less financial income), shares of profit or loss in a joint venture and depreciation and amortization. Adjusted EBIT and Adjusted EBITDA are determined by adding to EBIT and EBITDA, respectively (i) share-based compensation expenses, (ii) acquisition or divestiture-related expenses of business combinations, (iii) impairments and revaluation of fair value due to business combinations and (iv) costs incurred in relation to corporate initiatives, restructurings or reorganizations that are of a non-recurring nature. Management believes these non-IFRS measures to be important measures as they exclude the effects of items which primarily reflect the impact of financing decisions and, in the case of EBITDA and Adjusted EBITDA, long term investment, rather than the performance of the company’s day-to-day operations. The company also uses segment Adjusted EBITDA to evaluate the performance of its three business segments. As compared to net profit, these measures are limited in that they do not reflect the cash requirements necessary to service interest or principal payments on the company’s indebtedness and, in the case of EBITDA and Adjusted EBITDA, these measures are further limited in that they do not reflect the periodic costs of certain capitalized tangible and intangible assets used in generating revenues in the company’s business, or the changes associated with impairments. Management evaluates such items through other financial measures such as financial expenses, capital expenditures and cash flow provided by operating activities. The company believes that these measurements are useful to measure a company’s ability to grow or as a valuation measurement. The company’s calculation of EBIT, EBITDA, Adjusted EBIT and Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. EBIT, EBITDA, Adjusted EBIT and Adjusted EBITDA should not be considered as alternatives to net profit or any other performance measure derived in accordance with IFRS. The company’s presentation of EBIT, EBITDA, Adjusted EBIT and Adjusted EBITDA should not be construed to imply that its future results will be unaffected by unusual or non-recurring items.

Exchange Rate

This document contains translations of certain euro amounts into U.S. dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from euros to U.S. dollars in this document were made at a rate of EUR 1.00 to USD 1.1750, the reference rate of the European Central Bank on December 31, 2025.

Conference Call and Webcast

Materialise will hold a conference call and simultaneous webcast to discuss its financial results for the fourth quarter of 2025 on Thursday, February 19, 2026, at 8:30 a.m. ET/2:30 p.m. CET. Company participants on the call will include Brigitte de Vet-Veithen, Chief Executive Officer; and Koen Berges, Chief Financial Officer. A question-and-answer session will follow management’s remarks. To access the call by phone, please click the link below at least 15 minutes prior to the scheduled start time and you will be provided with dial-in details. Participants can choose to dial in or receive a call to connect to Materialise’s conference call.

Fourth Quarter 2025 Conference Call.

The conference call will also be broadcast live over the internet with an accompanying slide presentation, which can be accessed on the company’s website at http://investors.materialise.com. A webcast of the conference call will be archived on the company's website for one year.

About Materialise

Materialise NV incorporates more than three decades of 3D printing experience into a range of software solutions and 3D printing services that empower sustainable 3D printing applications. Our open, secure, and innovative end-to-end solutions enable flexible industrial manufacturing and mass personalization in various industries — including healthcare, automotive, aerospace, eyewear, art and design, wearables, and consumer goods. Headquartered in Belgium and with branches worldwide, Materialise NV combines the largest group of software developers in the industry with one of the world's largest and most complete 3D printing facilities. For additional information, please visit: www.materialise.com.

Cautionary Statement on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, our intentions, beliefs, assumptions, projections, outlook, analyses or current expectations, plans, objectives, strategies and prospects, both financial and business, including statements concerning, among other things, our estimates for the current fiscal year’s revenue and Adjusted EBIT, our results of operations, cash needs, capital expenditures, expenses, financial condition, liquidity, prospects, growth and strategies (including how our business, results of operations and financial condition could be impacted by the current armed geopolitical conflicts around the world and governmental responses thereto, inflation, increased labor, energy and materials costs), policy changes resulting from the U.S. presidential administration, changes in tariffs and trade restrictions, and the trends and competition that may affect the markets, industry or us. Such statements are subject to known and unknown uncertainties and risks. When used in this press release, the words “estimate,” “expect,” “anticipate,” “project,” “plan,” “intend,” “believe,” “forecast,” “will,” “may,” “could,” “might,” “aim,” “should,” and variations of such words or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the expectations of management under current assumptions at the time of this press release. These expectations, beliefs and projections are expressed in good faith and the company believes there is a reasonable basis for them. However, the company cannot offer any assurance that our expectations, beliefs and projections will actually be achieved. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and industry change, and depend on economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. We caution you that forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. All of the forward-looking statements are subject to risks and uncertainties that may cause the company's actual results to differ materially from our expectations, including risk factors described in the company's most recent annual report on Form 20-F filed with the U.S. Securities and Exchange Commission. There are a number of risks and uncertainties that could cause the company's actual results to differ materially from the forward-looking statements contained in this press release.

The company is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise, unless it has obligations under the federal securities laws to update and disclose material developments related to previously disclosed information.

Consolidated income statements (Unaudited)

for the three months ended

December 31,

for the twelve months

ended December 31,

In '000

2025

2025

2024

2025

2024

U.S.$

€

€

€

€

Revenue

82,442

70,164

65,680

267,633

266,765

Cost of Sales

(34,513)

(29,373)

(29,315)

(114,684)

(115,940)

Gross Profit

47,929

40,791

36,365

152,949

150,826

Gross profit as % of revenue

58.1%

58.1%

55.4%

57.1%

56.5%

Research and development expenses

(14,235)

(12,115)

(12,099)

(46,089)

(44,400)

Sales and marketing expenses

(19,042)

(16,206)

(16,490)

(61,591)

(61,620)

General and administrative expenses

(12,474)

(10,617)

(10,402)

(40,122)

(39,597)

Net other operating income (expenses)

1,478

1,258

1,357

3,789

4,223

Operating (loss) profit

3,656

3,111

(1,268)

8,936

9,432

Financial expenses

2,088

1,777

1,113

(5,616)

(2,969)

Financial income

732

623

2,188

3,968

7,677

(Loss) profit before taxes

6,476

5,510

2,033

7,287

14,139

Income Taxes

817

695

874

429

(733)

Net (loss) profit for the period

7,293

6,206

2,907

7,716

13,406

Net (loss) profit attributable to:

The owners of the parent

7,292

6,206

2,917

7,718

13,436

Non-controlling interest

-

-

(10)

(2)

(30)

Earning per share attributable to owners of the parent

Basic

0.12

0.11

0.05

0.13

0.23

Diluted

0.12

0.11

0.05

0.13

0.23

Weighted average basic shares outstanding

59,067

59,067

59,067

59,067

59,067

Weighted average diluted shares outstanding

59,077

59,077

59,148

59,072

59,105

Consolidated statements of comprehensive income (Unaudited)

for the three months ended

December 31,

for the twelve months

ended December 31,

In 000€

2025

2025

2024

2025

2024

U.S.$

€

€

€

€

Net profit (loss) for the period

7,293

6,206

2,907

7,716

13,406

Other comprehensive income

Recycling

Exchange difference on translation of foreign operations

(2,848)

(2,424)

(1,478)

(1,257)

(1,795)

Non-recycling

Fair value adjustments through OCI - Equity instruments

304

258

3

258

3

Other comprehensive income (loss), net of taxes

(2,544)

(2,165)

(1,475)

(999)

(1,792)

Total comprehensive income (loss) for the year, net of taxes

4,748

4,041

1,432

6,718

11,615

Total comprehensive income (loss) attributable to:

The owners of the parent

4,749

4,042

1,445

6,712

11,647

Non-controlling interests

(2)

(1)

(13)

5

(34)

Consolidated statement of financial position (Unaudited)

As of

December 31,

As of

December 31,

In 000€

2025

2024

Assets

Non-current assets

Goodwill

43,161

43,391

Intangible assets

25,639

29,973

Property, plant & equipment

112,854

111,331

Right-of-Use assets

5,429

7,719

Deferred tax assets

3,971

3,523

Investments in convertible loans

-

3,994

Other non-current assets

5,983

5,893

Total non-current assets

197,038

205,823

Current assets

Inventories

14,904

16,992

Trade receivables

54,938

53,052

Other current assets

15,533

18,166

Cash and cash equivalents

133,918

102,304

Assets held for sale

4,314

-

Total current assets

223,607

190,513

Total assets

420,646

396,336

As of

December 31,

As of

December 31,

In 000€

2025

2024

Equity and liabilities

Equity

Share capital

4,487

4,487

Share premium

203,895

233,895

Retained earnings and other reserves

47,180

10,196

Equity attributable to the owners of the parent

255,562

248,578

Non-controlling interest

(80)

(86)

Total equity

255,482

248,492

Non-current liabilities

Loans & borrowings

49,726

23,175

Lease liabilities

3,063

5,112

Deferred tax liabilities

2,660

3,202

Deferred income

17,344

13,268

Other non-current liabilities

486

910

Total non-current liabilities

73,280

45,666

Current liabilities

Loans & borrowings

7,759

10,383

Lease liabilities

2,565

2,614

Trade payables

20,125

23,348

Tax payables

748

1,432

Deferred income

43,523

45,998

Other current liabilities

16,362

18,403

Liabilities held for sale

802

-

Total current liabilities

91,884

102,178

Total equity and liabilities

420,646

396,336

Consolidated statement of cash flows (Unaudited)

for the twelve months

ended December 31,

In 000€

2025

2024

Operating activities

Net (loss) profit for the period

7,716

13,406

Non-cash and operational adjustments

23,179

18,655

Depreciation of property plant & equipment

15,274

15,372

Amortization of intangible assets

6,431

6,435

(Gain) on bargain purchase

-

(23)

Share-based payment expense

266

285

Loss (gain) on disposal of intangible assets and property, plant & equipment

(85)

(312)

Government grants

(319)

(57)

Movement in provisions

(184)

539

Movement reserve for bad debt and slow moving inventory

723

236

Financial income

(3,957)

(7,575)

Financial expense

5,612

3,012

Impact of foreign currencies

(136)

29

(Deferred) income taxes

(446)

714

Working capital adjustments

(8,843)

(1,418)

Decrease (increase) in trade receivables and other receivables

(2,671)

(1,037)

Decrease (increase) in inventories and contracts in progress

(904)

(372)

Increase (decrease) in deferred revenue

(265)

1,270

Increase (decrease) in trade payables and other payables

(5,003)

(1,279)

Income tax paid

(1,076)

(3,152)

Interest received

4,343

3,965

Net cash flow from operating activities

25,319

31,456

for the twelve months ended

December 31,

In 000€

2025

2024

Investing activities

Purchase of property, plant & equipment

(14,092)

(24,649)

Purchase of intangible assets

(2,169)

(1,728)

Proceeds from the sale of property, plant & equipment & intangible assets (net)

389

458

Acquisition of subsidiary (net of cash)

-

(2,670)

Convertible loan to third party

2,500

-

Capital government grants received

3,669

-

Net cash flow used in investing activities

(9,703)

(28,588)

Financing activities

Proceeds from loans & borrowings

35,000

-

Repayment of loans & borrowings

(11,054)

(23,267)

Repayment of leases

(3,067)

(3,122)

Capital increase

-

-

Interest paid

(1,712)

(1,337)

Other financial income (expense)

(2,145)

81

Dividends paid to equity holders of the parent

0

-

Net cash flow from (used in) financing activities

17,023

(27,644)

Net increase/(decrease) of cash & cash equivalents

32,638

(24,776)

Cash & Cash equivalents at the beginning of the year

102,304

127,573

Exchange rate differences on cash & cash equivalents

(1,024)

(492)

Cash & cash equivalents at end of the period

133,918

102,304

Reconciliation of Net Profit (Loss) to EBITDA and Adjusted EBITDA (Unaudited)

for the three months ended

December 31,

for the twelve months

ended December 31,

In 000€

2025

2024

2025

2024

Net profit (loss) for the period

6,206

2,907

7,716

13,406

Income taxes

(695)

(874)

(429)

733

Financial expenses

(1,777)

(1,113)

5,616

2,969

Financial income

(623)

(2,188)

(3,968)

(7,677)

Depreciation and amortization

5,544

5,501

21,785

21,742

EBITDA

8,655

4,234

30,721

31,175

Share-based compensation expense (1)

74

72

266

285

Restructuring and corporate initiatives (2)

795

-

1,400

-

Acquisition-related expenses of business combinations (3)

-

-

-

24

Adjusted EBITDA

9,524

4,306

32,386

31,484

(1) Share-based compensation expense represents the cost of equity-settled and share-based payments to employees.

(2) Non-recurring costs related to corporate initiatives, restructurings or reorganizations

(3) Acquisition-related expenses of business combinations represent expenses incurred in connection with the acquisition of Feops.

Reconciliation of Net Profit (Loss) to EBIT and Adjusted EBIT (Unaudited)

for the three months ended

December 31,

for the twelve months

ended December 31,

In 000€

2025

2024

2025

2024

Net profit (loss) for the period

6,206

2,907

7,716

13,406

Income taxes

(695)

(874)

(429)

733

Financial expenses

(1,777)

(1,113)

5,616

2,969

Financial income

(623)

(2,188)

(3,968)

(7,677)

EBIT

3,111

(1,268)

8,936

9,432

Share-based compensation expense (1)

74

72

266

285

Restructuring and corporate initiatives (2)

795

-

1,400

-

Acquisition-related expenses of business combinations (3)

-

-

-

24

Adjusted EBIT

3,980

(1,195)

10,601

9,741

(1) Share-based compensation expense represents the cost of equity-settled and share-based payments to employees.

(2) Non-recurring costs related to corporate initiatives, restructurings or reorganizations

(3) Acquisition-related expenses of business combinations represent expenses incurred in connection with the acquisition of Feops.

Segment P&L (Unaudited)

In 000€
Materialise
Medical

Materialise
Software

Materialise
Manufacturing

Total
segments

Unallocated
(1)

Consolidated

For the three months ended December 31, 2025

Revenues

37,016

10,974

22,174

70,164

(0)

70,164

Segment (adj) EBITDA

13,024

1,701

(2,199)

12,526

(3,001)

9,524

Segment (adj) EBITDA %

35.2%

15.5%

-9.9%

17.9%

13.6%

For the three months ended December 31, 2024

Revenues

31,837

11,124

22,719

65,680

0

65,680

Segment (adj) EBITDA

9,547

1,123

(2,989)

7,681

(3,375)

4,306

Segment (adj) EBITDA %

30.0%

10.1%

-13.2%

11.7%

6.6%

In 000€
Materialise
Medical

Materialise
Software

Materialise
Manufacturing

Total
segments

Unallocated
(1)

Consolidated

For the twelve months ended December 31, 2025

Revenues

134,239

40,907

92,486

267,633

(0)

267,633

Segment (adj) EBITDA

42,983

5,469

(4,236)

44,217

(11,830)

32,386

Segment (adj) EBITDA %

32.0%

13.4%

-4.6%

16.5%

12.1%

For the twelve months ended December 31, 2024

Revenues

116,358

43,899

106,508

266,765

0

266,765

Segment (adj) EBITDA

35,562

5,562

1,660

42,784

(11,300)

31,484

Segment (adj) EBITDA %

30.6%

12.7%

1.6%

16.0%

11.8%

(1) Unallocated segment adjusted EBITDA consists of corporate research and development and corporate other operating income (expense), and the added share-based compensation expenses, acquisition or divestiture-related expenses of business combinations, impairments and revaluation of fair value of business combinations and non-recurring costs related to corporate initiatives, restructurings and reorganizations that are included in Adjusted EBITDA and that are not allocated to the reporting segments.

Reconciliation of Net Profit (Loss) to Segment adjusted EBITDA (Unaudited)

for the three months ended

December 31,

for the twelve months

ended December 31,

In 000€

2025

2024

2025

2024

Net profit (loss) for the period

6,206

2,907

7,716

13,406

Income taxes

(695)

(874)

(429)

733

Financial expenses

(1,777)

(1,113)

5,616

2,969

Financial income

(623)

(2,188)

(3,968)

(7,677)

Operating (loss) profit

3,111

(1,268)

8,936

9,432

Depreciation and amortization

5,544

5,501

21,785

21,742

Corporate research and development

1,022

1,006

3,949

3,681

Corporate headquarter costs

3,562

2,717

12,048

10,254

Other operating income (expense)

(713)

(276)

(2,901)

(2,350)

Segment restructuring and reorganization

-

-

400

-

Acquisition-related expenses of business combinations (1)

-

-

-

24

Segment adjusted EBITDA

12,526

7,681

44,217

42,784

(1) Acquisition-related expenses of business combinations represent expenses incurred in connection with the acquisition of Feops.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260218190654/en/
Investor Relations Contact

Harriet Fried

Alliance Advisors Investor Relations

212.838.3777

hfried@allianceadvisors.com

Original: Materialise Reports Fourth Quarter and Full Year 2025 Results